Abstract
The novel triazole D0870 was tested for in vitro activity, as well as in vivo in a murine model of pulmonary blastomycosis. In vitro, D0870 had inhibitory and fungicidal activity against Blastomyces dermatitidis (MIC = 0.048 microgram/ml; minimal fungicidal concentration = 0.097 microgram/ml). In vivo, D0870 was approximately 100-fold more active than fluconazole on the basis of milligrams per kilogram of body weight given once daily (QD) against blastomycosis. D0870 doses of both 1 or 10 mg/kg given QD and 10 or 100 mg/kg given every other day prolonged survival (P < 0.001) over fluconazole (100 mg/kg given QD). A D0870 dosage of 1 mg/kg QD was equivalent to fluconazole given at 100 mg/kg in reduction of lung burdens of B. dermatitidis, and D0870 administered at 10 mg/kg QD and 10 or 100 mg/kg every other day caused greater reduction (P < 0.001). However, D0870 at 100 mg/kg given QD was lethally toxic, whereas fluconazole at 100 mg/kg was not. These results indicate that D0870 is an effective therapy for murine blastomycosis and should be further tested.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Brummer E., Hanson L. H., Stevens D. A. SCH 39304 in the treatment of acute or established murine pulmonary blastomycosis. Antimicrob Agents Chemother. 1991 Apr;35(4):788–790. doi: 10.1128/aac.35.4.788. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Clemons K. V., Stevens D. A. Comparative efficacies of amphotericin B lipid complex and amphotericin B deoxycholate suspension against murine blastomycosis. Antimicrob Agents Chemother. 1991 Oct;35(10):2144–2146. doi: 10.1128/aac.35.10.2144. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Harvey R. P., Schmid E. S., Carrington C. C., Stevens D. A. Mouse model of pulmonary blastomycosis: utility, simplicity, and quantitative parameters. Am Rev Respir Dis. 1978 Apr;117(4):695–703. doi: 10.1164/arrd.1978.117.4.695. [DOI] [PubMed] [Google Scholar]
- Hay R. J. Fluconazole. J Infect. 1990 Jul;21(1):1–6. doi: 10.1016/0163-4453(90)90508-6. [DOI] [PubMed] [Google Scholar]
- Ryley J. F., McGregor S., Wilson R. G. Activity of ICI 195,739--a novel, orally active bistriazole--in rodent models of fungal and protozoal infections. Ann N Y Acad Sci. 1988;544:310–328. doi: 10.1111/j.1749-6632.1988.tb40416.x. [DOI] [PubMed] [Google Scholar]
- Tucker R. M., Hanson L. H., Brummer E., Stevens D. A. Activity of ICI 195,739, a new oral triazole, compared with that of ketoconazole in the therapy of experimental murine blastomycosis. Antimicrob Agents Chemother. 1989 Apr;33(4):573–575. doi: 10.1128/aac.33.4.573. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Tucker R. M., Haq Y., Denning D. W., Stevens D. A. Adverse events associated with itraconazole in 189 patients on chronic therapy. J Antimicrob Chemother. 1990 Oct;26(4):561–566. doi: 10.1093/jac/26.4.561. [DOI] [PubMed] [Google Scholar]
- Tucker R. M., Williams P. L., Arathoon E. G., Stevens D. A. Treatment of mycoses with itraconazole. Ann N Y Acad Sci. 1988;544:451–470. doi: 10.1111/j.1749-6632.1988.tb40443.x. [DOI] [PubMed] [Google Scholar]